RxDoctor Payments Data

Paul Bushkuhl, MD

General Practice · Kingston, NYNPI 1700987567

Payments from drug & device makers

$12,360in general payments, 2019–2025

Across 712 payments — averaging $17.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$861
  • Lilly USA, LLC$813
  • Johnson & Johnson$711
  • Viiv Healthcare Company$686
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$12,323100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca76$1,197
AbbVie(2 entities)61$1,057
GSK50$861
Lilly USA, LLC58$813
Johnson & Johnson(2 entities)33$711
Viiv Healthcare Company36$686
Pfizer33$646
Amgen42$608
Novo Nordisk38$562
Novartis28$439
Merck24$436
Bayer23$431
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC23$422
Gilead18$288
Exact Sciences10$218
Dexcom, Inc.10$194
Otsuka America Pharmaceutical, Inc.8$172
Takeda Pharmaceuticals U.S.A., Inc.7$132
Endo Pharmaceuticals Inc.8$119
Harmony Biosciences LLC5$113
Amarin Pharma, Inc.7$105
E.r. Squibb & Sons, L.L.C.6$105
Sanofi-aventis U.S. LLC3$93
Organogenesis Inc.6$83
Avanir Pharmaceuticals, Inc.4$80
Regeneron Healthcare Solutions, Inc.4$79
Astellas Pharma US Inc5$79
Aurinia Pharma U.S., Inc.3$73
Radius Health, Inc.3$71
Eisai Inc.4$70
Esperion Therapeutics, Inc.3$64
Organon2$62
Boehringer Ingelheim4$62
Antares Pharma, Inc.4$60
Misonix Inc3$58
Sunovion Pharmaceuticals Inc.3$55
Sobi, Inc3$52
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$47
Boston Scientific2$45
Paratek Pharmaceuticals, Inc.2$42
Seqirus USA Inc2$40
Endo USA, Inc.2$38
Inspire Medical Systems, Inc.2$38
Grifols USA, LLC2$37
Tandem Diabetes Care, Inc.2$37
Tetraphase Pharmaceuticals, Inc.2$37
Abbott2$34
Melinta Therapeutics, LLC2$32
IBSA Pharma Inc.2$28
Hologic Sales And Service, LLC2$28
Verona Pharma, Inc.1$28
Kyowa Kirin, Inc.1$26
Ultragenyx Pharmaceutical Inc.1$26
ARS Pharmaceuticals Operations, Inc.1$26
Sandoz1$25
Almatica Pharma LLC1$24
Aimmune Therapeutics, Inc.1$23
Sumitomo Pharma America, Inc.1$23
Indivior Inc.1$22
Neurocrine Biosciences, Inc.1$21

How this compares

$12,360 in reported general payments places this provider in the 95th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$212,998
Medicare patients
474
Services billed
2,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban129$140,444
MounjaroTirzepatide68$82,940
OzempicSemaglutide33$46,067
FarxigaDapagliflozin Propanediol42$41,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$38,649
TrulicityDulaglutide22$36,608
DescovyEmtricitabine/Tenofov Alafenam13$28,354
WegovySemaglutide15$25,015
XareltoRivaroxaban17$24,772
MyrbetriqMirabegron34$19,734
OxycontinOxycodone Hcl18$18,170
InvokanaCanagliflozin11$17,452
JardianceEmpagliflozin16$15,198
Tresiba Flextouch U-200Insulin Degludec27$14,552
Candesartan Cilexetil190$10,556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$646$140,444129 claims
Lilly USA, LLCMounjaro, Trulicity$813$119,54890 claims
Novo NordiskOzempic, Wegovy$562$71,08348 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$861$60,18397 claims
Johnson & JohnsonXarelto, Invokana$711$42,22428 claims
AstraZenecaFarxiga$1,197$41,08142 claims
GileadDescovy$288$28,35413 claims
Astellas Pharma US IncMyrbetriq$79$19,73434 claims
Boehringer IngelheimJardiance$62$15,19816 claims
AbbVieLinzess, Synthroid$1,057$12,15354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,764 general practice providers in New York.

Other general practice in Kingston

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →